The FDA has granted an Investigational Device Exemption (IDE) approval for FemBloc, a non-surgical permanent birth control device, enabling enrollment in the final phase of the FINALE pivotal trial. This milestone follows Part A of a multi-stage design and moves FemBloc closer to US pre-market approval, potentially making it the first non-surgical permanent birth control to reach commercialization in the United States.
Executive perspective
Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc., framed the IDE approval as a pivotal step toward US regulatory clearance. She emphasized that the approval could deliver a long-awaited, non-surgical option for permanent contraception to women in the United States, while noting that European and select other markets have already begun benefiting from FemBloc.
How FemBloc works
Insertion process: FemBloc delivers a proprietary blended polymer into both fallopian tubes using a patented delivery system.
Mechanism: The polymer induces permanent blockage through the formation of natural scar tissue after safe degradation.
Safety profile: The approach eliminates anesthesia, incisions, and recovery time, reducing infection risk and other surgical complications.
Positioning: The device is presented as a safer, more convenient, and potentially more affordable first-of-its-kind option for permanent birth control.
Regulatory and market context
Regulatory history: FemBloc received full regulatory approval in Europe in June 2025, the United Kingdom in August 2025, and New Zealand in September 2025.
Clinical data: Initial clinical results highlighted positive efficacy, five-year safety, and patient satisfaction.
Clinical trial framework
Study design: Data were drawn from three prospective, open-label clinical trials conducted at 25 US tertiary medical centers.
Participants: Women aged 21 to 45 years seeking permanent contraception and willing to use temporary contraception until documented bilateral tubal occlusion.
Exclusions: Prior tubal surgery or ectopic pregnancy, difficult cervical visualization, active cervix/endometrium/fallopian tube infection, suspected gynecological malignancy, uterine anomaly, or recent pregnancy termination within six weeks of the planned FemBloc procedure.
Follow-up schedule: A confirmation test occurred three months post-procedure, with adverse event assessments at six months, and pregnancy/safety evaluations conducted by phone one year after confirmation and annually for 2 to 5 years.
Efficacy and safety findings
Procedural success: A successful FemBloc procedure was achieved in 99.6% of the intention-to-treat population, with 90.8% completing the confirmation test.
Demographics: Approximately 79.9% of participants were multiparous, and 63.8% were using a hormonal contraceptive at screening.
Efficacy: The observed pregnancy rate was 0%, significantly below the 6% performance goal.
Safety signals: No serious adverse events, including uterine perforations or ectopic pregnancies, were reported over the study period.
Adverse events: During the five-year follow-up, common events included vaginal spotting (58.5%), pelvic or abdominal pain (37.1%), abdominal or uterine cramps (18.8%), nausea (3.5%), musculoskeletal cramps (2.6%), and abdominal bloating (1.3%). Most adverse events (61.1%) occurred on the day of the procedure, with 85.8% resolving within three days.
Overall interpretation: The data support a minimally invasive delivery method for a permanent birth control system, with favorable early tolerability and a strong efficacy signal.
Expert interpretation
Investigators contrasted FemBloc with historic surgical sterilization, noting that the non-surgical approach could offer fewer risks, fewer contraindications, and a potential cost advantage.
Related topics
Researchers Identify 4 PCOS Subtypes To Guide Treatment
Experts Review Safety of Popular Menopause Supplements Today
